Chenodeoxycholic Acid Test

Most people only think about their liver when something obvious goes wrong. By the time standard liver enzymes flag a problem, the underlying machinery has often been struggling for a while. CDCA (chenodeoxycholic acid) sits one layer deeper, inside the chemistry your liver actually does every day to make bile, recycle cholesterol, and send chemical signals to your gut, fat tissue, and immune system.

Tracking this single bile acid in your blood gives you a window into that system. It can shift in liver and bile duct disease, in cholesterol gallstone disease, in some heart disease populations, and in severe infections, often in patterns that routine blood work would not pick up.

What This Test Actually Measures

Your liver makes two main primary bile acids from cholesterol: cholic acid and chenodeoxycholic acid. After being released into your gut to help absorb fat, most of them are reabsorbed and recycled back to the liver in a loop called enterohepatic circulation. This test reports the concentration of CDCA in your serum at a single point in time.

CDCA does not just emulsify fat. It also activates two cellular receivers, called FXR (farnesoid X receptor) and TGR5, that influence bile acid production, glucose handling, fat storage, and inflammation. Because of this dual role as a digestive detergent and a signaling molecule, CDCA in your blood reflects three things at once: how much your liver is making, how well bile is flowing, and how the recycling loop is functioning.

The test typically reports the unconjugated form. Conjugated forms (GCDCA, glycochenodeoxycholic acid, and TCDCA, taurochenodeoxycholic acid) are usually run as separate tests and behave differently in cholestatic disease, where bile flow is blocked or sluggish.

Liver and Bile Duct Disease

Bile acids change in almost every type of chronic liver and bile duct disease, and CDCA along with its conjugated forms is one of the most studied. In primary biliary cholangitis and autoimmune hepatitis, serum bile acid patterns including CDCA shift in ways that distinguish these conditions from healthy controls, and they correlate with disease severity scores.

In nonalcoholic fatty liver disease (now called MASLD, metabolic dysfunction-associated steatotic liver disease) higher serum and fecal bile acid levels track with worsening liver fibrosis. In hepatitis B-related liver disease, panels that include taurine-conjugated CDCA discriminate between healthy people, chronic hepatitis B, cirrhosis, and liver cancer with strong accuracy, outperforming routine liver enzymes for staging.

In intrahepatic cholestasis of pregnancy, serum CDCA helps flag the condition as part of a bile acid panel, though it is not specific on its own and healthy pregnant women can also test positive. CDCA is not the gold standard for any single liver disease, but as part of a bile acid profile it adds information that ALT (alanine aminotransferase) and AST (aspartate aminotransferase) miss.

Heart Disease and Mortality

A cohort study of 1,730 adults with coronary artery disease (narrowed heart arteries) found that people with higher serum levels of unconjugated bile acids, including CDCA, had lower cardiovascular and all-cause death risk during follow-up. This is the opposite of what you might assume given that bile acids rise in liver disease.

In a separate study of nondiabetic adults on hemodialysis, higher CDCA was associated with more coronary artery calcification, a marker of artery stiffening. The two findings point in different directions, but they share a theme: CDCA carries information about how cholesterol and inflammation are being handled in the body, not just about the liver.

Other Disease Associations

CDCA shows up as a meaningful signal in several other conditions. In severe COVID-19 in older adults, CDCA and glycochenodeoxycholic acid drop sharply, and lower admission levels predict who progresses to worse disease. In acute pancreatitis, blood CDCA falls during the acute phase and rises again in recovery, and lower levels track with pancreatic tissue damage.

Lower serum CDCA has also been reported in schizophrenia and in people whose diabetic retinopathy has progressed from non-proliferative to proliferative stages. In cerebrotendinous xanthomatosis, a rare inherited disorder, the body cannot make CDCA properly, leading to neurological damage that improves when CDCA is replaced as a medication.

Why a Single Reading Can Cut Both Ways

On the surface, the evidence looks contradictory. High CDCA conjugates are common in cholestatic liver disease. Higher unconjugated CDCA in coronary artery disease patients was tied to lower death risk. Lower CDCA appears in severe COVID-19, acute pancreatitis, and some neurological conditions.

The framework that resolves this: CDCA is a phenotype indicator, not a simple high-bad, low-good marker. When bile flow is blocked, CDCA and its conjugates back up in the blood. When the liver and gut are functioning well, healthy unconjugated CDCA reflects normal bile acid synthesis and intact FXR signaling, which is anti-inflammatory and metabolically protective. When the liver is stressed by severe systemic illness, total bile acid synthesis can fall and CDCA drops with it. The clinical meaning depends on the context, the conjugated-to-unconjugated ratio, and what other markers show.

Reference Ranges

CDCA is currently a research and specialty marker. There are no standardized clinical cutpoints from major guideline bodies. The numbers below come from a study of healthy German adults measured by a sensitive lab method, and are presented as illustrative orientation rather than universal targets. Your lab will report different numbers depending on the assay used, and age and sex meaningfully shift the values, with men typically higher than women.

Compare your results within the same lab over time for the most meaningful trend, and do not treat any single threshold as a diagnostic line.

Tracking Your Trend

Bile acid levels move with the time of day, recent meals, and the condition of your gut. A single CDCA reading is a snapshot that can mislead you in either direction. The pattern across multiple readings carries far more information than any single value.

A reasonable cadence for a self-directed reader: get a baseline test under fasting conditions, retest in 3 to 6 months if you are making meaningful changes to diet, body weight, or medications that touch the liver or bile acid system, and at least annually thereafter to watch your trajectory.

What to Do With an Abnormal Result

An isolated abnormal CDCA result is rarely a diagnosis on its own. The next step is context. If your CDCA is persistently elevated, the most useful companion tests are the rest of the bile acid profile (cholic acid, deoxycholic acid, total bile acids), liver enzymes (ALT, AST, ALP for alkaline phosphatase, GGT for gamma-glutamyl transferase), and bilirubin to look for cholestasis or liver injury patterns.

If those companion markers are also abnormal, a hepatologist (liver specialist) is the right professional to involve, and imaging of the liver and bile ducts becomes a reasonable next step. If your CDCA is persistently low and you have unexplained neurological symptoms, cataracts at a young age, or a family history of unusual cholesterol-related disease, a metabolic specialist should be consulted to consider rare bile acid synthesis disorders.

When Results Can Be Misleading

• Recent meals: bile acids surge into the blood after eating. A non-fasting sample can look very different from a morning fasting draw and is harder to interpret.
• Acute illness: severe systemic infection or critical illness, including severe COVID-19, can sharply lower circulating CDCA for the duration of the illness without indicating chronic liver disease.
• Time of day and recent diet shifts: bile acid concentrations vary across the day and with the fat content of recent meals. A few days of an unusual diet can shift a single reading.
• Assay differences: CDCA is measured by specialized lab methods, and absolute values can vary between labs. A normal value at one lab may sit outside the reference range at another.